Back to Agenda
WHO/Swissmedic Signature Session - Towards Access 2030: How Can Strengthening of Regulatory Systems Contribute?
Session Chair(s)
Petra Doerr, PharmD, RPh
Director
European Directorate for the Quality of Medicines and Healthcare (EDQM), France
Murray M. Lumpkin, DrMed, MD, MSc
Deputy Director, Integrated Development, Lead for Global Reg Systems Initiative
Bill and Melinda Gates Foundation, United States
Various initiatives and programs are under way to improve access to quality medicines in low- and middle-income countries (LMIC). An important component of achieving this goal is to strengthen the regulatory systems of those countries. Many stakeholders (and many resources) are involved and engaged. However, what does Regulatory Systems Strengthening (RSS) actually mean in the context of Access 2030 in LMICs and do all these efforts show tangible results? What are the outcomes we are trying to achieve through RSS and how can we improve these outcomes?
Speaker(s)
Towards access 2030: An Overview of WHO Efforts in Regulatory Systems Strengthening
Emer Cooke, MBA, MSc
The European Medicines Agency, Netherlands
Executive Director, Chair, ICMRA
What Can Regulators in LMIC Do to Better Utilize the Scarce Resources in Order to Improve the Access to Priority Medicines?
Delese Mimi Darko, MBA, RPh, RAC
Food and Drugs Authority, Ghana
Chief Executive Officer
Panel Discussion
Thomas B. Cueni, MBA
IFPMA, Switzerland
Director General
Panel Discussion
Petra Doerr, PharmD, RPh
European Directorate for the Quality of Medicines and Healthcare (EDQM), France
Director
Panel Discussion
Guido Rasi, MD
Tor Vergata University of Rome, Italy
Chairman,Clinical Trial Center of Gemelli Polyclinic Inst; Prof of Microbiology
Panel Discussion
Nicola Bedlington
European Patient's Forum, Belgium
Special Advisor
Panel Discussion
Alex Schulze
Swiss Agency For Development Cooperation, Switzerland
Co-Head Division Global Programme Health
Panel Discussion
Hiiti Sillo, MSc, RPh
World Health Organization (WHO), Switzerland
Unit Head, Regulation and Safety, Department of Regulation and Prequalification
Panel Discussion
Nathalie Strub Wourgaft
Drugs For Neglected Diseases Initiative (dndi), Switzerland
Medical Director
Have an account?